US 12,247,246 B2
Identification of inhibitors of TcpC and TIR NADase activity
Jeffrey D. Milbrandt, St. Louis, MO (US); Aaron DiAntonio, St. Louis, MO (US); Kow Essuman, St. Louis, MO (US); Xianrong Mao, St. Louis, MO (US); Yo Sasaki, St. Louis, MO (US); and Dan Summers, St. Louis, MO (US)
Assigned to Washington University, St. Louis, MO (US)
Filed by Washington University, St. Louis, MO (US)
Filed on Nov. 29, 2022, as Appl. No. 18/059,838.
Application 18/059,838 is a division of application No. 16/651,196, abandoned, previously published as PCT/US2018/052969, filed on Sep. 26, 2018.
Claims priority of provisional application 62/563,447, filed on Sep. 26, 2017.
Prior Publication US 2023/0272449 A1, Aug. 31, 2023
Int. Cl. C07D 213/20 (2006.01); A61K 31/4425 (2006.01); A61K 31/4706 (2006.01); A61K 31/473 (2006.01); A61K 31/4965 (2006.01); A61P 31/00 (2006.01); A61P 33/00 (2006.01); C07D 219/10 (2006.01); C07D 241/20 (2006.01); C07D 401/06 (2006.01); C12Q 1/34 (2006.01)
CPC C12Q 1/34 (2013.01) [A61K 31/4425 (2013.01); A61K 31/4706 (2013.01); A61K 31/473 (2013.01); A61K 31/4965 (2013.01); G01N 2333/924 (2013.01)] 11 Claims
 
1. A method of treating a microbial infection in a subject in need thereof, wherein the microbe encodes a TIR NADase, the method comprising: administering to said subject a therapeutically effective amount of pharmaceutical composition comprising a TIR NADase inhibitor wherein the TIR NADase inhibitor is one or more of:

OG Complex Work Unit Chemistry
or pharmaceutically acceptable salts thereof.